ThermalTherapeutics Systems

ThermalTherapeutics is a biotechnology and medical device company specializing in the development of magnetic nanoparticle hyperthermia (mNPH) for interventional oncology. The company's proprietary platform involves the precise delivery of magnetic nanoparticles into solid tumors, which are then activated by an external alternating magnetic field to produce localized therapeutic heat. This thermal energy is used to either ablate the tumor directly or act as an adjuvant to increase the sensitivity of cancer cells to traditional treatments like radiation and chemotherapy. Currently focusing on high-unmet-need areas such as glioblastoma and prostate cancer, the company was founded as a collaboration between researchers at MD Anderson Cancer Center and Dartmouth College. Their approach aims to provide a minimally invasive alternative for treating deep-seated or recurrent tumors that are difficult to manage with surgery alone.